ImmuCell (ICCC) director Steven Rosgen granted 10,000 stock options at $5.49

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

ImmuCell Corp. director Steven T. Rosgen received a grant of 10,000 non-qualified stock options on Common Stock. The options have an exercise price of $5.49 per share, become exercisable on April 16, 2028, and expire on April 16, 2030. Following this compensation-related award, he holds 10,000 options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rosgen Steven T.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non Qualified Stock Options (Right to buy)	10,000	$0.00	--

Holdings After Transaction: Non Qualified Stock Options (Right to buy) — 10,000 shares (Direct)

Footnotes (1)

Key Figures

Options granted: 10,000 options Exercise price: $5.49 per share Exercise date: April 16, 2028 +2 more

5 metrics

Options granted 10,000 options Non-qualified stock options granted to director Steven T. Rosgen

Exercise price $5.49 per share Exercise price for the 10,000 stock options

Exercise date April 16, 2028 Date options become exercisable

Expiration date April 16, 2030 Date options expire if unexercised

Options held after grant 10,000 options Total derivative securities following transaction

Key Terms

Non Qualified Stock Options, grant/award acquisition, underlying security

3 terms

Non Qualified Stock Options financial

"security_title: "Non Qualified Stock Options (Right to buy)""

grant/award acquisition financial

"transaction_action: "grant/award acquisition""

underlying security financial

"underlying_security_title: "Common Stock""

Form 4 Insider Transactions: What Each Field Means →

04/14/2026 - 03:36 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rosgen Steven T.

(Last)

(First)

(Middle)

C/O IMMUCELL CORPORATION

56 EVERGREEN DRIVE

(Street)

PORTLAND

MAINE

04103

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMMUCELL CORP /DE/ [ ICCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non Qualified Stock Options (Right to buy)	$5.49	04/16/2025		A		10,000		04/16/2028	04/16/2030	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

Remarks:

The options were granted by the Issuer to compensate directors for services on the Issuer's board of directors.

	/s/ Timothy C. Fiori Attorney-in-Fact	04/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did ImmuCell (ICCC) director Steven T. Rosgen report in this Form 4?

Director Steven T. Rosgen reported receiving 10,000 non-qualified stock options on ImmuCell Common Stock. The award is a compensation-related grant, not a market purchase, and gives him the right to buy shares at a fixed exercise price in the future.

What are the key terms of Steven T. Rosgen’s 10,000 ImmuCell (ICCC) stock options?

The grant covers 10,000 non-qualified stock options with an exercise price of $5.49 per share. These options relate to ImmuCell Common Stock, giving him the right to acquire 10,000 shares if he exercises them under the stated terms.

When can Steven T. Rosgen exercise his ImmuCell (ICCC) stock options?

Steven T. Rosgen’s 10,000 non-qualified stock options become exercisable on April 16, 2028. After that date, he may choose to exercise them at the fixed $5.49 per-share price any time before the stated expiration date.

When do Steven T. Rosgen’s ImmuCell (ICCC) stock options expire?

The 10,000 non-qualified stock options granted to Steven T. Rosgen expire on April 16, 2030. If they are not exercised by that date, the right to buy ImmuCell Common Stock at $5.49 per share will lapse.

How many ImmuCell (ICCC) options does Steven T. Rosgen hold after this Form 4 transaction?

After this reported transaction, Steven T. Rosgen holds 10,000 non-qualified stock options directly. This total matches the size of the new award, indicating the filing reflects a single compensation-related grant of derivative securities.